Impax Asset Management Group plc Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Impax Asset Management Group plc grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,000 shares of the company's stock after purchasing an additional 35,000 shares during the quarter. Impax Asset Management Group plc owned about 0.08% of Neurocrine Biosciences worth $9,794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in NBIX. RFP Financial Group LLC raised its stake in Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company's stock worth $26,000 after buying an additional 149 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $28,000. Innealta Capital LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $30,000. New Covenant Trust Company N.A. acquired a new position in Neurocrine Biosciences during the 1st quarter worth approximately $32,000. Finally, EdgeRock Capital LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $35,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director William H. Rastetter sold 14,250 shares of the firm's stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the sale, the director now directly owns 37,491 shares of the company's stock, valued at $5,499,554.79. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the firm's stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now directly owns 37,491 shares in the company, valued at $5,499,554.79. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Gary A. Lyons sold 11,570 shares of the firm's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total transaction of $1,740,475.10. Following the completion of the sale, the director now owns 119,047 shares of the company's stock, valued at $17,908,240.21. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,063 shares of company stock valued at $7,023,330 over the last ninety days. 4.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on NBIX shares. HC Wainwright reaffirmed a "buy" rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 1st. Jefferies Financial Group upped their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a report on Monday, August 19th. Royal Bank of Canada reduced their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a report on Friday, October 4th. Robert W. Baird upped their target price on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an "outperform" rating in a report on Friday, August 2nd. Finally, Oppenheimer upped their target price on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an "outperform" rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded up $3.77 during trading hours on Wednesday, hitting $125.30. The company's stock had a trading volume of 1,207,781 shares, compared to its average volume of 865,550. The stock has a market cap of $12.69 billion, a price-to-earnings ratio of 32.58 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12 month low of $103.63 and a 12 month high of $157.98. The business has a 50-day simple moving average of $118.51 and a 200-day simple moving average of $133.33.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.